Literature DB >> 12607113

Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol.

Ching Yin Lee1, Larbi Krimbou, Jérôme Vincent, Chantal Bernard, Pierre Larramée, Jacques Genest, Michel Marcil.   

Abstract

Type A and B forms of Niemann-Pick disease (NPD) are lipid storage disorders caused by deficient activity of the enzyme acid sphingomyelinase (aSMase) and the resulting accumulation of sphingomyelin in tissues. In the present study, we investigated two family members who had been diagnosed with Type B NPD and who had a severe decrease in plasma high density lipoprotein cholesterol (HDL-C). The proband (a 48-year-old male) had an HDL-C of 0.30 mmol/l (12 mg/dl) and his sister had values of 0.45 mmol/l (17 mg/dl) with severe premature coronary artery disease (CAD). Hypertriglyceridemia was found in both cases. aSMase activity measured in skin fibroblasts appeared markedly depressed. The SMPD1 gene, coding for aSMase, was sequenced in affected subjects and all family members. Compound heterozygosity (DeltaR608 and R441X) was identified in both affected patients. Carriers of the DeltaR608 mutation tended to have moderately to severe decreased HDL-C levels, whereas carriers of the R441X mutation, although present only in young subjects (<20 years of age) had normal HDL-C levels. To investigate the cause of the low HDL-C level in these patients, we studied apoA-I-mediated cellular cholesterol efflux in fibroblasts. Unlike patients with Tangier disease, cholesterol efflux was found to be normal under the experimental conditions used in the present study. On the other hand, we observed a significant increase in the free cholesterol:esterified cholesterol ratio in HDL fraction from these patients and a decrease in endogenous lecithin-cholesterol acyltransferase (LCAT) activity, as determined by the fractional esterification rate. Taken together, these results suggest that (1) compound heterozygosity at the SMPD1 gene causes a severe decrease in aSMase activity and in HDL-C and increases the risk of CAD, (2) this lipoprotein abnormality is not attributable to defective cellular cholesterol efflux, (3) abnormal HDL composition might cause a decrease in LCAT activity and a lack of HDL maturation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12607113     DOI: 10.1007/s00439-002-0893-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  57 in total

Review 1.  Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing.

Authors:  E H Schuchman; S R Miranda
Journal:  Genet Test       Date:  1997

Review 2.  Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1.

Authors:  John F Oram
Journal:  Trends Mol Med       Date:  2002-04       Impact factor: 11.951

3.  Type A Niemann-Pick disease: a frameshift mutation in the acid sphingomyelinase gene (fsP330) occurs in Ashkenazi Jewish patients.

Authors:  O Levran; R J Desnick; E H Schuchman
Journal:  Hum Mutat       Date:  1993       Impact factor: 4.878

4.  The sphingolipidoses.

Authors:  R O Brady
Journal:  N Engl J Med       Date:  1966-08-11       Impact factor: 91.245

5.  Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene.

Authors:  S L Schissel; E H Schuchman; K J Williams; I Tabas
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

6.  Niemann-Pick type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients.

Authors:  O Levran; R J Desnick; E H Schuchman
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins.

Authors:  K A Rye; N J Hime; P J Barter
Journal:  J Biol Chem       Date:  1996-02-23       Impact factor: 5.157

8.  Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction.

Authors:  P V Subbaiah; M Liu
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

9.  The Nova Scotia (type D) form of Niemann-Pick disease is caused by a G3097-->T transversion in NPC1.

Authors:  W L Greer; D C Riddell; T L Gillan; G S Girouard; S M Sparrow; D M Byers; M J Dobson; P E Neumann
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

10.  Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization.

Authors:  M Marcil; B Boucher; L Krimbou; B C Solymoss; J Davignon; J Frohlich; J Genest
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-08       Impact factor: 8.311

View more
  13 in total

Review 1.  Genetics of cholesterol efflux.

Authors:  Iulia Iatan; Aurélien Palmyre; Sarah Alrasheed; Isabelle Ruel; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  Treatment of hyperlipidemia associated with Niemann-Pick disease type B by fenofibrate.

Authors:  Jin-Ho Choi; Young-Lim Shin; Gu-Hwan Kim; Soo-Jong Hong; Han-Wook Yoo
Journal:  Eur J Pediatr       Date:  2005-10-07       Impact factor: 3.183

Review 3.  Genetic lipoprotein disorders and coronary atherosclerosis.

Authors:  Mahmoud Alawadhi; George Thanassoulis; Michel Marcil; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2005-05       Impact factor: 5.113

4.  Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease.

Authors:  Calogera M Simonaro; Jae-Ho Park; Efrat Eliyahu; Nataly Shtraizent; Margaret M McGovern; Edward H Schuchman
Journal:  Am J Hum Genet       Date:  2006-03-14       Impact factor: 11.025

Review 5.  Types A and B Niemann-Pick disease.

Authors:  Edward H Schuchman; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-12-16       Impact factor: 4.797

Review 6.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

7.  A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Roberto Giugliani; Bruno Bembi; Marie T Vanier; Eugen Mengel; Scott E Brodie; David Mendelson; Gwen Skloot; Robert J Desnick; Noriko Kuriyama; Gerald F Cox
Journal:  Pediatrics       Date:  2008-07-14       Impact factor: 7.124

Review 8.  The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.

Authors:  E H Schuchman
Journal:  J Inherit Metab Dis       Date:  2007-07-12       Impact factor: 4.982

9.  R542X mutation in SMPD1 gene: genetically novel mutation with phenotypic features intermediate between type A and type B Niemann-Pick disease.

Authors:  Aradhana Aneja; Aditi Sharma; Ashwin Dalal; Vishal Sondhi
Journal:  BMJ Case Rep       Date:  2012-11-27

Review 10.  Sphingomyelin in high-density lipoproteins: structural role and biological function.

Authors:  Roberto Martínez-Beamonte; Jose M Lou-Bonafonte; María V Martínez-Gracia; Jesús Osada
Journal:  Int J Mol Sci       Date:  2013-04-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.